Cian Healthcare Ltd.
Snapshot View

17.75 ▼0%

18 May 2022, 04:01:00 PM

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.cian.co
Market Cap 44.37 Cr.
Enterprise Value(EV) 112.38 Cr. 2021-03
Financial Indicators
Earnings per share (EPS) 0.02 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 835.55 Trailing Twelve Months Ending 2021-03
Industry PE 28.41 Trailing Twelve Months Ending 2021-03
Book Value / Share 22.21 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.80 Calculated using Price: 17.75
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 2.50 Cr. 24,995,764 Shares
FaceValue 10
Company Profile

The Company was originally incorporated as ‘Cian Healthcare Private Limited’ at Pune, Maharashtra as a private limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated January 07, 2003 issued by Registrar of Companies, Pune, Maharashtra. Subsequently, the Company was converted into a public limited Company pursuant to special resolution passed by the shareholders at the Extraordinary General Meeting held on November 19, 2018 and fresh certificate of incorporation consequently upon change of name was issued by Registrar of Companies, Pune, Maharashtra dated November 30, 2018 and name of the Company was changed to Cian Healthcare Limited.

The Company is a WHO-GMP & ISO -9001:2015 certified transnational manufacturing Company with wide range of Pharmaceutical, Nutraceutical, Ayurvedic, Cosmeceuticals, Sexual Wellness and Food supplement products. The Company has a full-fledged F&D and regulatory department. The Company complies with the standard manufacturing practices as laid down by the World Health Organization and is also certified by the Food and Drug Control Administration.

Business area of the Company:

 The Company develops, manufactures and commercializes pharmaceutical products including sales, marketing, quality assurance, distribution, compliance and regulatory aspects under 12 therapeutic segments like Orthopaedics, Gynaecology, Paediatrics, Cardiac, Diabetic, Dermatology, Pain Management, Antibiotics, Neuro, Critical Care, Gastro-Intestinal and Nutraceuticals, along with 10 sales division focused on developing and growing its engagements in specialist and super specialist division. The company works under different business models like Brand Business, Export, Third Party Manufacturing and Government Supplies. The Company manufactures innovative products comprising of Tablets, Capsules, Liquid Orals, Ointments, Creams, Lotions, Gels and Sachet. The Company has special licence for manufacturing veterinary products for client like SAVAvet and Venky’s.

Major Events and Milestones:

  • 2003: Incorporated as Cian Healthcare Private Limited
  • 2006: Started selling through franchise business in Sangli, Western Part of Maharashtra
  • 2008: Shifted its base to Pune for the further establishment of the Company
  • 2013: The manufacturing unit at Roorkee in Uttarakhand started with state of art manufacturing facilities
  • 2013: Got accreditation of WHO GMP and ISO 9001: 2008
  • 2018: Got accreditation of WHO GMP and ISO 9001: 2015
  • 2018: Conversion from Private Limited to Public Limited

Awards, Achievements and Accolades:

  • 2014: Kissey Kamyabi Ke - Promising Entrepreneur by Zee Business
  • 2014: India’s Small Giant Award Awarded Kalraj Mishra, Hon’ble Union Cabinet Minister of MSME, Govt of India.
  • 2014: Indian Top 100 SME by Ministry of Commerce.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
-6.58%
1 Month
-17.44%
3 Month
-12.78%
6 Month
+1.14%
1 Year
+7.90%
2 Year
+11.99%
5 Year
10 Year
2 years 2020-03 2021-03
Return on Equity (%) -7.54 0.10
Return on Capital Employed (%) 3.00 6.99
Return on Assets (%) -2.42 0.03

Balance Sheet View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 58 58
Non Curr. Liab. 50 41
Curr. Liab. 48 58
Minority Int.
Equity & Liab. 157 157
Non Curr. Assets 94 88
Curr. Assets 54 63
Misc. Exp. not W/O 8 5
Total Assets 157 157

Profit Loss View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 57 74
Other Income 1 0
Total Income 58 74
Total Expenditure -50 -62
PBIDT 8 12
Interest -7 -8
Depreciation -4 -3
Taxation 0 -1
Exceptional Items 0 0
PAT -4 0
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit -4 0
Adjusted EPS -2 0

Cash Flow View Details

Particulars 2 years 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -7 6
Cash Fr. Inv. -27 3
Cash Fr. Finan. 36 -10
Net Change 1 -1
Cash & Cash Eqvt 3 2

Shareholding Pattern View Details

8 Qtrs 2018-09 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 96.60 70.89 70.89 70.89 70.89 70.89 66.26 66.26
Public 3.40 29.11 29.11 29.11 29.11 29.11 33.74 33.74
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 10.14 10.14 10.14 10.14 20.14 14.11 34.11

Announcements View Details

Sat, 30 Apr 2022
In Compliance Under Regulation 40(9) & (10) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 Regarding Submission Of The Certificate Of Compliance Report Issued By DSM & ASSOCIATES Company Secretaries For The Year Ended On 31St March 2022.
In Compliance Under Regulation 40(9) & (10) of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 regarding submission of the Certificate of Compliance Report issued by DSM & ASSOCIATES Company Secretaries for the Year ended on 31st March 2022.
Fri, 22 Apr 2022
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial Year Ended 31St March 2022.
Submission of Compliance Certificate under Regulation 7(3) of the SEBI (LODR) Regulations 2015 for the Half Year/Year ended on 31st March 2022.
Wed, 20 Apr 2022
Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- MUNJAJI DHUMAL
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Wed, 18 May 2022
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week Low Close Crossing Last Week Low
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%